FDA ApprovedFDA Approved

Tirzepatide

Dual GIP/GLP-1 Receptor Agonist | Weight Loss & Diabetes

Tirzepatide is a revolutionary dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. FDA-approved for both type 2 diabetes management and chronic weight management, it has demonstrated unprecedented efficacy for weight loss and metabolic health optimization. Tirzepatide works by mimicking incretin hormones that regulate blood sugar, slow gastric emptying, and reduce appetite, offering superior results compared to single-mechanism GLP-1 agonists.

Daily dose

2.5-15mg weekly

Frequency

Once weekly

Cycle length

12-24+ weeks

Storage

2-8°C (refrigerated)

Key benefits

Dramatic weight loss (15-22% body weight), superior diabetes control, reduced cardiovascular risk, improved insulin sensitivity, appetite suppression, preserved muscle mass

How it works

Dual agonist of GIP and GLP-1 receptors, glucose-dependent insulin stimulation, gastric emptying delay, glucagon suppression, central satiety signaling through hypothalamic pathways

Dosage protocols

Goal

Weight loss initiation

Dose

2.5mg weekly · Once weekly

Route

SubQ injection

Goal

Weight loss progression

Dose

5mg weekly · Once weekly

Route

SubQ injection

Goal

Weight loss optimization

Dose

7.5-10mg weekly · Once weekly

Route

SubQ injection

Goal

Maximum weight loss

Dose

12.5-15mg weekly · Once weekly

Route

SubQ injection

Goal

Diabetes management (mild)

Dose

5-7.5mg weekly · Once weekly

Route

SubQ injection

Goal

Diabetes management (severe)

Dose

10-15mg weekly · Once weekly

Route

SubQ injection

Research indications

weight Loss

Severe Obesity Management — Clinical trials demonstrate 15-22% body weight reduction in non-diabetic obese individuals - superior to all existing weight loss medications including semaglutide

Metabolic Syndrome Reversal — Comprehensive improvement in waist circumference, blood pressure, triglycerides, HDL cholesterol, and insulin resistance markers

Body Composition Optimization — Preferentially reduces visceral adipose tissue while preserving lean muscle mass when combined with resistance training and adequate protein

diabetes

Type 2 Diabetes Management — FDA-approved for T2DM with superior HbA1c reduction (1.5-2.4%) compared to existing GLP-1 agonists and insulin regimens

Insulin Resistance Improvement — Significantly improves insulin sensitivity indices and glucose tolerance in prediabetic, diabetic, and metabolically healthy obese populations

Beta Cell Preservation — Protects pancreatic beta cell function and may help restore glucose-responsive insulin secretion in early diabetes

cardiovascular

Cardiovascular Risk Reduction — SURPASS-CVOT trial showed 26% reduction in major adverse cardiovascular events in high-risk diabetic patients

Blood Pressure Management — Significant reductions in both systolic (8-12 mmHg) and diastolic blood pressure independent of weight loss effects

Lipid Profile Enhancement — Improves triglycerides (-20-30%), increases HDL cholesterol, reduces small dense LDL particles and apolipoprotein B

Administration

injectable

Interactions

Avoid Combination

Semaglutide — Both are GLP-1 agonists - combining increases hypoglycemia and severe GI side effect risk

Avoid Combination

Liraglutide — Another GLP-1 agonist - dual therapy contraindicated due to additive effects

Monitor Combination

Insulin — May require significant insulin dose reduction due to improved sensitivity and glucose control

Synergistic

Metformin — Complementary mechanisms for diabetes management and weight loss with enhanced efficacy

Compatible

CJC-1295 — Growth hormone support may help preserve muscle mass during rapid weight loss

Compatible

Ipamorelin — May help maintain metabolic rate and muscle preservation during caloric restriction

Compatible

BPC-157 — No known interactions, may support gut health and reduce GI side effects

Compatible

5-Amino-1MQ — NNMT inhibition may complement GLP-1 effects for enhanced metabolic optimization

Safety notes

Start with lowest dose (2.5mg) and escalate gradually every 4 weeks to minimize side effects

Contraindicated with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2

Monitor for signs of acute pancreatitis (severe, persistent abdominal pain radiating to the back)

Significant nausea is common initially but typically improves - stay hydrated and eat smaller meals

Requires prescription and medical supervision - not available over-the-counter

Store in refrigerator between 2-8°C, never freeze or shake vigorously

May require adjustment of other diabetes medications to prevent hypoglycemia

Research studies

SURMOUNT-2 T2DM Trial (2023)

938 adults with T2DM and obesity | 72-week duration

15mg dose achieved 15.7% weight loss with significant improvements in all cardiometabolic parameters

SURPASS-CVOT Cardiovascular Outcomes (2023)

12,785 T2DM patients | 3.5-year follow-up | Primary prevention study

26% reduction in major adverse cardiovascular events, establishing cardioprotective benefits

SURMOUNT-1 Phase 3 Trial (2022)

2,539 adults with obesity | 72-week study | Multiple dose levels

15mg weekly dose achieved 22.5% weight loss vs 2.4% placebo - largest weight loss seen in pharmaceutical trials

SURPASS Clinical Program (2021-2022)

Multiple Phase 3 trials | >13,000 T2DM patients | Head-to-head comparisons

Superior HbA1c reduction and weight loss compared to insulin, semaglutide, and all existing diabetes medications

Related compounds

Semaglutide Retatrutide Bioglutide Mazdutide